PATENT CLAIM ANALYSIS

Application Number: 16084668
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["424", "450000"]

Abstract:
Disclosed is an Edaravone dosage form and a use thereof in preparing a drug used for treating diseases related to oxidative stress, the dosage form being selected from a lipid-based delivery system, a solid dispersion, micelles and a co-solvent based formulation.

Claim (Index 4):
The lipid-based drug delivery system of  claim 3 , wherein the water-soluble organic solvent is selected from PEG 200-10,000 (e.g., PEG 300, PEG 400, PEG 1,000 and PEG 6,000), polyvinyl caprolactam (PCL), polyvinyl acetate (PVA) or a copolymer thereof, a water-soluble form of vitamin E and ethanol; the surfactant is selected from Cremophor RH 40, Labrasol, TPGS 1000, Tween 20, Cremophor El and Tween 80; the co-surfactant is selected from PEG 300, PEG 400, propylene glycol, glycerol, ethanol, Transcutol HP and Transcutol P; and the polymer solubilizer is selected from Soluplus, Chitosan, poly(vinyl pyrrolidone) (PVP), PVP/VA, HPC, HPMC, HPMCAS, eudragit E100, and a cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 97.0
- Lexical Diversity: 1.25
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15844365', '13884182', '12876292', '13707122', '13414369']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7365431813527837
- 35 USC 102 Novelty (BERT): 0.5037707290995161
- Combined Prediction Score: 0.713265936127457
- Mean Citation Score: 214.404466
- Max Citation Score: 254.98409
- Similarity Product: 182.22049807014344

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test